Drug Profile

Exidavnemab - Bioarctic

Alternative Names: ABBV-0805; BAN-0805; PD-0805

Latest Information Update: 16 May 2025

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator BioArctic
Developer AbbVie; BioArctic
Class Antiparkinsonians; Monoclonal antibodies
Mechanism of Action Alpha-synuclein inhibitors

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

Yes - Multiple system atrophy
New Molecular Entity Yes
Available For Licensing Yes

Highest Development Phases

Phase II Multiple system atrophy; Parkinson's disease

Most Recent Events

08 May 2025 The regulatory authorities approves the inclusion of Multiple system atrophy patients in the phase IIa EXIST trial in Spain in Poland
17 Mar 2025 Preclinical trials in Multiple system atrophy in Sweden (Parenteral)
17 Mar 2025 Exidavnemab - Bioarctic receives Orphan Drug status for Multiple system atrophy in USA

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com